Medicine pack check sheet

Source-linked reading points

• This public label lists 100 mg and 400 mg film-coated tablets, both scored. mg identifies the stated strength per tablet, and the score is formulation information in this exact label; neither permits self-splitting, combining, adjusting, converting from another person's regimen or substituting another imatinib product.
• For inability to swallow film-coated tablets, the label gives a specific procedure for dispersing this exact tablet in water or apple juice and using it immediately after disintegration. It does not mean all oncology tablets may be crushed, stored, mixed with food or handled the same way; the actual pack needs review against the current target-market label by the haematology/oncology team or pharmacist.
• The label flags CYP3A inducers/inhibitors, other medicines metabolised through CYP3A4 or CYP2D6, anticoagulation and high-dose methotrexate as co-medication issues. Anti-infectives, anticoagulants, thyroid medicine, herbs, supplements and every prescription/OTC product should be reviewed with the actual packages; a webpage cannot decide individual co-use, spacing or adjustment.
• With rapid weight gain or marked swelling, bleeding, fever, jaundice-like changes, severe abdominal pain, breathing or chest symptoms, marked weakness or another acute concern, contact the treatment team promptly or use local urgent medical support. Do not self-pause, restart or change to another targeted medicine from a webpage, package image, one test result or another patient's experience.